Eurocine Vaccines AB (publ) (8X4.F)

0.0874 -0.0008 (-0.91%) At close: 08:03AM CET

Eurocine Vaccines AB (publ)

Nanna Svartz vAeg 4
Solna 171 65
Sweden
46 7 06 34 01 71
https://www.eurocine-vaccines.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Hans Arwidsson Ph.D.	CEO, Pres & Director	N/A	N/A	1958
Dr. Anna-Karin Maltais	Chief Scientific Officer, VP of R&D and Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Marie Olliver	Director of Clinical Devel.	N/A	N/A	N/A

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden. It has a research and collaboration agreement with Spixia Biotechnology AB to develop, manufacture, and commercialize chlamydia vaccine candidates. The company was incorporated in 1999 and is based in Solna, Sweden.

Corporate Governance

Eurocine Vaccines AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.